Compare HSBC Holdings plc (HSBC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Neurocrine Biosciences Inc — how do they compare? HSBC Holdings plc trades at $101.09 (market cap $335.21B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: HSBC Holdings plc is far larger — about 19.3× Neurocrine Biosciences Inc's market cap, and HSBC Holdings plc pays a 3.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HSBC | NBIX | |
|---|---|---|
Market Cap | $335.21B | $17.40B |
Sector | Technology | Health |
52-Week High | $100.61 | $180.55 |
52-Week Low | $61.30 | $123.10 |
Dividend Yield | 3.79% | — |
Enterprise Value | — | $16.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
